Oversight of Clinical Investigators:

Action Needed to Improve Timeliness and Enhance Scope of FDA's Debarment and Disqualification Processes for Medical Product Investigators

GAO-09-807: Published: Sep 25, 2009. Publicly Released: Oct 22, 2009.

Additional Materials:

Contact:

Marcia G. Crosse
(202) 512-3407
contact@gao.gov

 

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

The Food and Drug Administration (FDA) oversees the clinical investigators who conduct research involving new drugs, biologics, and medical devices to ensure that their conduct does not compromise the safety of clinical trial participants or the integrity of clinical trial data. FDA can debar or disqualify investigators who have engaged in misconduct such as submitting fraudulent data. Debarred or disqualified investigators cannot engage in certain activities related to clinical research. GAO was asked to review FDA's debarment and disqualification processes. GAO examined the length of time debarment and disqualification processes have taken and factors for those time frames, and the statutory and regulatory limitations of debarment and disqualification. GAO reviewed laws, regulations, and FDA files through November 5, 2008, for (1) all investigators, study coordinators, and sub-investigators for whom FDA pursued debarment since receiving debarment authority in 1992; and (2) all clinical investigators for whom FDA pursued disqualification since FDA adopted its current process for initiating proceedings in 1998.

More than half of the debarment proceedings in GAO's review took 4 or more years, and factors contributing to these time frames included internal control weaknesses in the debarment process and competing priorities among responsible staff. FDA has statutory authority to debar individuals who have been convicted of felonies or certain misdemeanors related to the development, approval, or regulation of a drug or biologic. For the 18 proceedings GAO reviewed, the length of time from an individual's conviction through debarment (or as of November 5, 2008, for pending proceedings) ranged from about 1 year to nearly 11 years. Factors that contributed to delays included that FDA staff faced competing priorities and FDA had not established internal controls, such as time frames for the completion of steps in the debarment process. FDA has made or planned changes that could improve timeliness (e.g., by establishing time frames in March 2009), but the effects of such actions have yet to be seen. The time taken for disqualification proceedings varied and proceedings took longer when the investigator contested disqualification. FDA may disqualify investigators who repeatedly or deliberately failed to comply with FDA regulations or submitted false information to FDA or the sponsor of a clinical trial. For the 52 disqualification proceedings GAO reviewed, the length of time from initiation of a disqualification proceeding to its conclusion (or as of November 5, 2008, for pending proceedings) ranged from 26 days to more than a decade, with about one-third taking more than 2 years. In general, the more steps taken by the investigator to contest disqualification, the longer it took to complete the proceeding. Disqualification proceedings initiated in 1998 through 2001 generally took longer than proceedings that were initiated more recently. FDA officials told us that a lack of time frames for these proceedings--an internal control weakness--may have contributed to longer proceedings. FDA made changes to its disqualification process (e.g., by establishing time frames in June 2008 and January 2009) that could further improve timeliness, but the full effect of these changes remains to be seen. FDA's debarment authority does not fully extend to involvement with medical devices, and its regulations do not extend disqualification for drugs and biologics to medical devices and vice versa. As a result, an individual may be debarred from involvement with drugs and biologics, but not from involvement with medical devices, regardless of the kind of misconduct in which the individual engaged. FDA's disqualification regulations allow an investigator who is disqualified for conduct related to drugs or biologics to serve as an investigator for medical devices; likewise, an individual who FDA disqualified for conduct related to medical devices remains able to serve as a clinical investigator for drugs and biologics.

Status Legend:

More Info
  • Review Pending-GAO has not yet assessed implementation status.
  • Open-Actions to satisfy the intent of the recommendation have not been taken or are being planned, or actions that partially satisfy the intent of the recommendation have been taken.
  • Closed-implemented-Actions that satisfy the intent of the recommendation have been taken.
  • Closed-not implemented-While the intent of the recommendation has not been satisfied, time or circumstances have rendered the recommendation invalid.
    • Review Pending
    • Open
    • Closed - implemented
    • Closed - not implemented

    Recommendations for Executive Action

    Recommendation: The Commissioner of FDA should take the necessary steps to pursue debarment authority for medical devices that is consistent with the current debarment authority for drugs and biologics and prohibit any debarred individual from involvement with drugs, biologics, and medical devices.

    Agency Affected: Department of Health and Human Services: Public Health Service: Food and Drug Administration

    Status: Closed - Not Implemented

    Comments: In its written comments on a draft of our report, FDA indicated that having debarment authority to prohibit individuals and companies convicted of certain crimes, or otherwise involved in criminal activity, from involvement in the medical device industry would benefit the development and approval process for medical devices. FDA subsequently confirmed its support for extending its debarment authority to include persons involved in the medical device industry. A bill that would grant FDA this authority was introduced and referred to the House Committee on Energy and Commerce, Subcommittee on Health, in October, 2009, but was not enacted. In July 2013, the agency reported that it has taken no further action on this recommendation and suggested that we close it. Given that implementation of this recommendation seems unlikely, we are closing it as not implemented.

    Recommendation: The Commissioner of FDA should take the necessary steps to amend FDA regulations to ensure that those who have engaged in misconduct found sufficiently serious to warrant disqualification for one investigational medical product are not able to continue to serve as clinical investigators for any.

    Agency Affected: Department of Health and Human Services: Public Health Service: Food and Drug Administration

    Status: Closed - Implemented

    Comments: On April 30, 2012, FDA issued a final rule amending the regulations to expand the scope of clinical investigator disqualification. Under this rule, when the Commissioner of FDA determines that an investigator is ineligible to receive one kind of test article (drugs, devices, or new animal drugs), the investigator will also be ineligible to conduct any clinical investigation that supports an application for research or marketing permit for other kinds of products regulated by FDA. When it issued this final rule, FDA stated that the rule is based in part upon GAO's recommendation. Amending its regulations to expand the scope of investigator disqualification is intended to help ensure adequate protection of research subjects and the quality and integrity of data submitted to FDA.

    Recommendation: The Commissioner of FDA should take the necessary steps to monitor compliance with recently established time frames for debarment and disqualification proceedings and take appropriate action when those are not met.

    Agency Affected: Department of Health and Human Services: Public Health Service: Food and Drug Administration

    Status: Closed - Implemented

    Comments: FDA agreed with GAO's recommendation and took steps to implement it, including establishment of procedural requirements, development of tracking systems, and issuance of guidance. In addition, FDA has monitored the timeliness of debarment and disqualification proceedings and taken actions when steps are not completed in a timely way. Timely completion of these proceedings is critical to ensuring that individuals who have engaged in misconduct are prohibited from repeating the misconduct--that is, the actions that compromised the quality or integrity of clinical trial data or jeopardized the safety of clinical trial participants--and that individuals whose explanations FDA finds to be satisfactory can have their proceedings concluded quickly.

    Apr 8, 2014

    Apr 2, 2014

    Mar 26, 2014

    Mar 24, 2014

    Mar 10, 2014

    Mar 7, 2014

    Mar 6, 2014

    Mar 4, 2014

    Looking for more? Browse all our products here